Bio-Thera Solutions Ltd (688177) - Total Assets
Based on the latest financial reports, Bio-Thera Solutions Ltd (688177) holds total assets worth CN¥2.39 Billion CNY (≈ $349.02 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bio-Thera Solutions Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Bio-Thera Solutions Ltd's total assets have evolved over time, based on quarterly financial data. Also see how much is Bio-Thera Solutions Ltd worth for the company's overall valuation and market capitalisation.
Bio-Thera Solutions Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Bio-Thera Solutions Ltd's total assets of CN¥2.39 Billion consist of 41.9% current assets and 58.1% non-current assets. Review Bio-Thera Solutions Ltd total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.6% |
| Accounts Receivable | CN¥164.70 Million | 7.2% |
| Inventory | CN¥312.42 Million | 13.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥218.44 Million | 9.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Bio-Thera Solutions Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Bio-Thera Solutions Ltd stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Thera Solutions Ltd's current assets represent 41.9% of total assets in 2025, a decrease from 46.9% in 2016.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2025, up from 1.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 13.7% of total assets.
Bio-Thera Solutions Ltd Competitors by Total Assets
Key competitors of Bio-Thera Solutions Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Bio-Thera Solutions Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.86 | 3.67 |
| Quick Ratio | 0.42 | 0.64 | 3.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-484.66 Million | CN¥-171.31 Million | CN¥981.84 Million |
Bio-Thera Solutions Ltd - Advanced Valuation Insights
This section examines the relationship between Bio-Thera Solutions Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 36.67 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | CN¥2.29 Billion |
| Market Capitalization | $1.28 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bio-Thera Solutions Ltd's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bio-Thera Solutions Ltd's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bio-Thera Solutions Ltd (2016–2025)
The table below shows the annual total assets of Bio-Thera Solutions Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.29 Billion ≈ $334.71 Million |
+3.71% |
| 2024-12-31 | CN¥2.21 Billion ≈ $322.74 Million |
-3.57% |
| 2023-12-31 | CN¥2.29 Billion ≈ $334.67 Million |
+4.93% |
| 2022-12-31 | CN¥2.18 Billion ≈ $318.96 Million |
-16.73% |
| 2021-12-31 | CN¥2.62 Billion ≈ $383.06 Million |
+9.39% |
| 2020-12-31 | CN¥2.39 Billion ≈ $350.19 Million |
+135.93% |
| 2019-12-31 | CN¥1.01 Billion ≈ $148.43 Million |
-0.63% |
| 2018-12-31 | CN¥1.02 Billion ≈ $149.37 Million |
+64.92% |
| 2017-12-31 | CN¥618.94 Million ≈ $90.57 Million |
-12.61% |
| 2016-12-31 | CN¥708.29 Million ≈ $103.65 Million |
-- |
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more